CMMB

Chemomab Therapeutics Ltd DRC

Healthcare Biotechnology

Portfolio

Watchlist

1.35 USD 0.01 ( 0.37%)

Last update at 2026-11-11T21:00:00Z

VOLUME

58796

Market Cap

18.10M

Momentum Score

…

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range

1.28

Low

1.42

High

52 Week Price Range

1.35

Low

3.58

High

Momentum Score

…

Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

AI Summary

Publicly available information on Chemomab Therapeutics Ltd is limited; company disclosures indicate it is a development-stage biopharmaceutical listed on NASDAQ focused on oncology. Long-term growth may depend on clinical trial progress, regulatory readouts and licensing or partnership agreements, which could provide catalysts for value creation.

Key risks include high clinical and regulatory uncertainty, likely need for external financing and dilution, and limited public disclosure that makes assessing the pipeline and prospects difficult.

Risk Score

High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close

1.34

Dividend Yield

Revenue TTM

0.00M

Revenue Per Share

Gross Profit TTM

0.00M

Debt / Equity

0.02

ROE

-82.17%

Net Debt

-7.56M

ROCE

-78.18%

Diluted EPS TTM

-0.97

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Income before tax	-9.07M	-13.95M	-24.22M	-28.18M	-12.48M
Net income	-9.07M	-13.95M	-24.22M	-27.65M	-12.55M
Selling general administrative	3.73M	0.00M	7.08M	11.56M	6.03M
Selling and marketing expenses	-	-	7.05M	-	-
Gross profit	-0.07M	-0.05M	-0.07M	-	-
Reconciled depreciation	0.07M	0.05M	0.07M	0.06M	0.03M
Ebit	-9.64M	-14.01M	-25.46M	-28.53M	-12.40M
Ebitda	-9.57M	-13.96M	-25.39M	-28.48M	-12.37M
Depreciation and amortization	0.07M	0.05M	0.07M	0.06M	0.03M
Operating income	-9.64M	-14.74M	-25.46M	-28.53M	-12.40M
Other operating expenses	9.64M	14.74M	25.46M	28.53M	12.37M
Interest expense	-	-	-	0.35M	0.11M
Tax provision	0.00M	0.00M	0.00M	-0.53M	-
Interest income	0.57M	0.79M	1.24M	-	-
Net interest income	0.57M	0.79M	1.24M	0.35M	-0.11M
Income tax expense	-	-	-0.00M	-0.53M	0.08M
Total revenue	0.00M	0.00M	0.00M	0.00M	0.00M
Total operating expenses	9.57M	14.74M	25.46M	28.53M	12.37M
Cost of revenue	0.07M	0.05M	0.07M	-	-
Total other income expense net	0.58M	0.79M	1.24M	0.35M	-0.08M
Net income from continuing ops	-8.99M	-13.95M	-24.22M	-27.65M	-12.48M
Net income applicable to common shares	-	-	-	-27.65M	-12.48M

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total assets	13.81M	16.96M	22.15M	43.06M	64.35M
Intangible assets	0.01M	0.01M	-	-	-
Other current assets	-	1.51M	1.04M	1.38M	47.50M
Total liab	1.48M	3.43M	5.15M	6.84M	2.89M
Total stockholder equity	12.33M	13.54M	17.00M	36.22M	61.47M
Other current liab	0.99M	2.44M	4.25M	4.94M	1.21M
Capital stock	0.00M	0.00M	0.00M	0.00M	0.00M
Retained earnings	-111.62M	-102.62M	-88.68M	-63.82M	-36.17M
Other assets	-	-	-	0.73M	0.96M
Cash	7.56M	6.07M	9.37M	13.52M	14.69M
Total current liabilities	1.48M	3.22M	4.84M	6.75M	2.65M
Net debt	-7.56M	-5.75M	-8.98M	-13.30M	-14.34M
Short term debt	-	0.12M	0.08M	0.12M	0.11M
Short long term debt total	-	0.32M	0.39M	0.21M	0.34M
Other stockholder equity	123.95M	116.16M	105.68M	100.04M	97.64M
Property plant equipment	-	-	-	0.59M	0.70M
Total current assets	13.42M	16.04M	20.90M	41.74M	62.69M
Long term investments	-	-	-	-	0.00M
Net tangible assets	-	-	-	36.22M	61.47M
Short term investments	2.80M	8.20M	10.49M	26.37M	46.48M
Net receivables	3.06M	0.26M	0.29M	0.46M	1.53M
Inventory	-	0.00M	-1.04M	-	-47.50M
Accounts payable	0.48M	0.67M	0.52M	1.69M	1.34M
Accumulated other comprehensive income	-	0.00M	-	-	-
Non currrent assets other	0.21M	0.38M	0.56M	0.73M	0.96M
Non current assets total	0.39M	0.92M	1.25M	1.33M	1.67M
Capital lease obligations	0.00M	0.32M	0.39M	0.21M	0.34M

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Investments	-	2.30M	15.88M	19.53M	-45.19M
Change to liabilities	-	-	-	0.35M	1.18M
Total cashflows from investing activities	5.43M	-	-	19.53M	-45.19M
Total cash from financing activities	7.21M	9.87M	3.50M	-0.81M	61.07M
Change to operating activities	-	-	-	3.72M	-1.07M
Net income	-9.07M	-13.95M	-24.22M	-27.65M	-12.48M
Change in cash	1.42M	-3.22M	-4.23M	-1.65M	3.51M
Begin period cash flow	6.15M	9.37M	13.60M	15.24M	11.73M
End period cash flow	7.56M	6.15M	9.37M	13.60M	15.24M
Total cash from operating activities	-11.22M	-15.39M	-23.61M	-20.37M	-12.37M
Issuance of capital stock	7.14M	9.87M	3.50M	0.27M	58.64M
Depreciation	0.07M	0.05M	0.07M	0.06M	0.03M
Other cashflows from investing activities	-	2.30M	15.88M	19.60M	1.00M
Change to inventory	-	-	-0.00M	0.00M	0.00M
Change to account receivables	-	-	0.00M	-0.00M	-0.00M
Sale purchase of stock	-	0.00M	0.00M	-1.22M	0.00M
Other cashflows from financing activities	-	-	15.88M	0.14M	2.44M
Change to netincome	-	-	-	3.21M	2.02M
Capital expenditures	0.00M	0.00M	0.00M	0.07M	0.24M
Change in working capital	-2.86M	-2.11M	-0.95M	4.01M	-1.95M
Stock based compensation	0.62M	0.62M	1.49M	3.21M	2.02M
Other non cash items	0.63M	0.67M	-0.00M	2.96M	0.91M
Free cash flow	-11.22M	-15.39M	-23.61M	-20.44M	-12.61M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to EBITDA (x)
CMMB Chemomab Therapeutics Ltd DRC	0.01 0.37%	1.35	-	12.94	-	2.07	0.33
NVO Novo Nordisk A/S	0.41 1.00%	41.10	41.58	31.15	2.13	32.99	4.70
VRTX Vertex Pharmaceuticals Inc	-0.86 0.16%	547.03	30.22	24.27	10.36	6.50	24.66
REGN Regeneron Pharmaceuticals Inc	43.35 4.73%	959.41	29.07	20.12	7.57	3.82	19.42
ARGNF argenx SE	- -%	900.30	45.77	31.25	13.84	7.12	36.06

Profile*

Chemomab Therapeutics Ltd DRC

Address

Building C, Tel Aviv-Yafo, Israel, 6158101

Contact

972 77 331 0156

Website

https://www.chemomab.com

Name	Title	Year Born
Dr. Dale R. Pfost Ph.D.	Chairman & CEO	1957
Dr. Adi Mor George Ph.D.	Co-Founder, Chief Scientific Officer & Exec. Director	1982
Mr. Donald R. Marvin MBA	CFO, Exec. VP & COO	1953
Barbara Lindheim	Consulting VP of Investor & PR, Strategic Communications	NA
Mr. Mitchell Lawrence Jones M.D., Ph.D.	VP of Corp. Devel. & Strategy	NA
Dr. Matthew Frankel M.B.A., M.D.	Chief Medical Officer & VP of Drug Devel.	NA
Dr. Adi Mor George Ph.D.	Co-Founder, Chief Scientific Officer, CEO & Executive Director	1982
Ms. Sigal Fattal CPA, M.B.A.	Chief Financial Officer	1971
Dr. Matthew B. Frankel M.B.A., M.D.	Chief Medical Officer & VP of Drug Development	1969
Barbara Lindheim	Consulting Vice President of Investor & Public Relations, Strategic Communications	NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

Top Gainers*
Top Losers*

Equity Sectors*

Basic Materials

-1.70%
Communication Services

+0.33%
Consumer Cyclical

+0.45%
Consumer Defensive

-0.56%
Energy

-0.25%
Financial Services

+0.49%
Healthcare

+0.20%
Industrials

+0.74%
Real Estate

+1.71%
Technology

-2.81%
Utilities

+0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

TYT	GBX 3102.38 +3.03%
CPG	GBX 33.81 -1.11%
DGED	GBX 93.25 -1.26%
LTOD	GBX 37.75 -1.44%
KNM	GBX 24500.00 +2.04%

DAR	GBX 8.30 +23.42%
VTY	GBX 276.20 +8.23%
GTCO	GBX 0.09 +6.98%
GLV	GBX 2.34 +6.36%
BUR	GBX 249.20 +5.95%

TMI	GBX 0.72 -6.49%
HSBA	GBX 1291.40 -5.42%
RKT	GBX 5218.00 -4.85%
TGA	GBX 643.00 -4.03%
RKH	GBX 61.70 -3.89%